Symbols / ARTL $4.15 +10.37%
ARTL Chart
About
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.94M |
| Enterprise Value | 3.02M | Income | -12.88M | Sales | — |
| Book/sh | -1.89 | Cash/sh | 0.85 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7 | IPO | — |
| P/E | — | Forward P/E | -4.72 | PEG | — |
| P/S | — | P/B | -2.20 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 0.15 |
| Current Ratio | 0.17 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -37.56 | EPS next Y | -0.88 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-24 08:00 | ROA | -190.09% |
| ROE | -16.25% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 708.26K |
| Shs Float | 705.07K | Short Float | 2.50% | Short Ratio | 1.67 |
| Short Interest | — | 52W High | 85.80 | 52W Low | 3.15 |
| Beta | 1.07 | Avg Volume | 24.70K | Volume | 97.65K |
| Target Price | — | Recom | None | Prev Close | $3.76 |
| Price | $4.15 | Change | 10.37% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$4.15
Latest analyst target
3. DCF / Fair value
$-105.94
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.15
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-19 | down | Maxim Group | Buy → Hold | — |
| 2025-09-08 | down | D. Boral Capital | Buy → Hold | — |
| 2025-08-26 | main | D. Boral Capital | Buy → Buy | $18 |
| 2025-08-18 | main | D. Boral Capital | Buy → Buy | $18 |
| 2025-08-06 | main | D. Boral Capital | Buy → Buy | $18 |
| 2025-08-04 | main | D. Boral Capital | Buy → Buy | $18 |
| 2025-07-08 | up | D. Boral Capital | Hold → Buy | $20 |
| 2025-06-11 | down | D. Boral Capital | Buy → Hold | — |
| 2025-06-06 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-04-28 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-04-02 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-03-04 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-03 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-02-27 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-01-14 | main | D. Boral Capital | Buy → Buy | $6 |
| 2024-12-09 | main | D. Boral Capital | Buy → Buy | $6 |
| 2024-12-09 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-06-05 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
- Artelo shrinks share count to 708K in 3-for-1 reverse split - Stock Titan Fri, 06 Mar 2026 13
- AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI Mon, 16 Mar 2026 15
- 12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga Mon, 16 Mar 2026 17
- Price-Driven Insight from (ARTL) for Rule-Based Strategy - Stock Traders Daily Sat, 14 Mar 2026 19
- Artelo Biosciences Stock Soars 114% After Promising Depression Treatment Data - MSN Sat, 14 Mar 2026 17
- Activity Recap: Is ARTL stock showing strong momentum - Earnings Overview Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn Mon, 16 Mar 2026 23
- Artelo Biosciences announces 3-for-1 reverse stock split - Yahoo Finance Sat, 07 Mar 2026 08
- Artelo Biosciences Announces Reverse Stock Split - TradingView Fri, 06 Mar 2026 13
- Artelo Biosciences (Nasdaq: ARTL) plans 3-for-1 reverse stock split in March 2026 - Stock Titan Fri, 06 Mar 2026 13
- Artelo Biosciences implements 3-for-1 reverse stock split - Investing.com South Africa Fri, 06 Mar 2026 20
- Artelo Biosciences Prices $3 Mln Public Offering Of Common Stock And Warrants - Nasdaq hu, 04 Sep 2025 07
- Cancer appetite, pain and depression drugs: Artelo’s 2025 trial gains - Stock Titan ue, 24 Feb 2026 08
- Artelo Biosciences Announces Reverse Stock Split - The Globe and Mail Fri, 06 Mar 2026 13
- Artelo Biosciences announces reverse stock split - MSN Fri, 06 Mar 2026 15
- ARTL SEC Filings - Artelo Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan Sat, 28 Feb 2026 11
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 38346 | 136128 | — | Conversion of Exercise of derivative security at price 3.55 per share. | MATSUI CONNIE L | Director | — | 2025-10-28 00:00:00 | D |
| 1 | 9586 | 34030 | — | Conversion of Exercise of derivative security at price 3.55 per share. | GORGAS GREGORY D | Chief Executive Officer | — | 2025-10-28 00:00:00 | D |
| 2 | 6846 | 24303 | — | Conversion of Exercise of derivative security at price 3.55 per share. | FAVORITO TAMARA A. | Director | — | 2025-10-28 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -11.40M | -10.11M | -10.57M | -10.29M |
| TotalUnusualItems | -1.20M | 282.00K | 641.00K | 207.00K |
| TotalUnusualItemsExcludingGoodwill | -1.20M | 282.00K | 641.00K | 207.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -12.88M | -9.83M | -9.29M | -10.08M |
| EBITDA | -12.60M | -9.83M | -9.93M | -10.08M |
| EBIT | -12.60M | -9.83M | -9.93M | -10.08M |
| NetInterestIncome | -277.00K | 0.00 | 0.00 | -3.00K |
| InterestExpense | 277.00K | 0.00 | 0.00 | 5.00K |
| InterestIncome | 0.00 | 2.00K | 2.00K | |
| NormalizedIncome | -11.68M | -10.11M | -9.93M | -10.29M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -12.88M | -9.83M | -9.29M | -10.08M |
| TotalExpenses | 11.40M | 10.11M | 9.93M | 10.29M |
| TotalOperatingIncomeAsReported | -11.40M | -10.11M | -9.93M | -10.29M |
| DilutedAverageShares | 537.00K | 493.33K | 472.17K | 207.50K |
| BasicAverageShares | 537.00K | 493.33K | 472.17K | 207.50K |
| DilutedEPS | -18.30 | -18.84 | -21.36 | -35.82 |
| BasicEPS | -18.30 | -18.84 | -21.36 | -35.82 |
| DilutedNIAvailtoComStockholders | -12.88M | -9.83M | -9.29M | -10.08M |
| NetIncomeCommonStockholders | -12.88M | -9.83M | -9.29M | -10.08M |
| NetIncome | -12.88M | -9.83M | -9.29M | -10.08M |
| NetIncomeIncludingNoncontrollingInterests | -12.88M | -9.83M | -9.29M | -10.08M |
| NetIncomeContinuousOperations | -12.88M | -9.83M | -9.29M | -10.08M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -12.88M | -9.83M | -9.29M | -10.08M |
| OtherIncomeExpense | -1.20M | 282.00K | 641.00K | 207.00K |
| SpecialIncomeCharges | -1.16M | 0.00 | ||
| OtherSpecialCharges | 1.16M | |||
| GainOnSaleOfSecurity | -40.00K | 282.00K | 641.00K | 207.00K |
| NetNonOperatingInterestIncomeExpense | -277.00K | 0.00 | 0.00 | -3.00K |
| InterestExpenseNonOperating | 277.00K | 0.00 | 0.00 | 5.00K |
| InterestIncomeNonOperating | 0.00 | 2.00K | 2.00K | |
| OperatingIncome | -11.40M | -10.11M | -9.93M | -10.29M |
| OperatingExpense | 11.40M | 10.11M | 9.93M | 10.29M |
| ResearchAndDevelopment | 5.42M | 5.99M | 5.70M | 4.32M |
| SellingGeneralAndAdministration | 5.98M | 4.12M | 4.23M | 5.96M |
| GeneralAndAdministrativeExpense | 5.98M | 4.12M | 4.23M | 5.96M |
| OtherGandA | 5.98M | 4.12M | 4.23M | 5.96M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 2.02M | 567.58K | 531.49K | 475.95K |
| ShareIssued | 2.02M | 567.58K | 531.49K | 475.95K |
| NetDebt | 9.00K | |||
| TotalDebt | 678.00K | 104.00K | 23.00K | 63.00K |
| TangibleBookValue | -3.31M | 818.00K | 9.71M | 17.36M |
| InvestedCapital | -663.00K | 2.86M | 11.75M | 19.40M |
| WorkingCapital | -3.35M | 785.00K | 9.69M | 17.32M |
| NetTangibleAssets | -3.31M | 818.00K | 9.71M | 17.36M |
| CapitalLeaseObligations | 69.00K | 104.00K | 23.00K | 63.00K |
| CommonStockEquity | -1.27M | 2.86M | 11.75M | 19.40M |
| TotalCapitalization | -1.27M | 2.86M | 11.75M | 19.40M |
| TotalEquityGrossMinorityInterest | -1.27M | 2.86M | 11.75M | 19.40M |
| StockholdersEquity | -1.27M | 2.86M | 11.75M | 19.40M |
| GainsLossesNotAffectingRetainedEarnings | -272.00K | -202.00K | -203.00K | -254.00K |
| OtherEquityAdjustments | -272.00K | -202.00K | -203.00K | -254.00K |
| RetainedEarnings | -63.02M | -50.14M | -40.31M | -31.02M |
| AdditionalPaidInCapital | 62.01M | 53.19M | 52.26M | 50.67M |
| CapitalStock | 2.00K | 1.00K | 3.00K | 3.00K |
| CommonStock | 2.00K | 1.00K | 3.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 4.07M | 1.84M | 1.29M | 1.02M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 29.00K | 69.00K | 0.00 | 23.00K |
| LongTermDebtAndCapitalLeaseObligation | 29.00K | 69.00K | 0.00 | 23.00K |
| LongTermCapitalLeaseObligation | 29.00K | 69.00K | 0.00 | 23.00K |
| CurrentLiabilities | 4.04M | 1.77M | 1.29M | 998.00K |
| OtherCurrentLiabilities | -3.00K | |||
| CurrentDebtAndCapitalLeaseObligation | 649.00K | 35.00K | 23.00K | 40.00K |
| CurrentCapitalLeaseObligation | 40.00K | 35.00K | 23.00K | 40.00K |
| CurrentDebt | 609.00K | |||
| OtherCurrentBorrowings | 609.00K | |||
| PayablesAndAccruedExpenses | 3.40M | 1.74M | 1.27M | 958.00K |
| CurrentAccruedExpenses | 15.00K | 0.00 | ||
| InterestPayable | 15.00K | 0.00 | ||
| Payables | 3.38M | 1.74M | 1.27M | 958.00K |
| DuetoRelatedPartiesCurrent | 345.00K | 61.00K | 30.00K | 53.00K |
| AccountsPayable | 3.04M | 1.68M | 1.24M | 905.00K |
| TotalAssets | 2.80M | 4.70M | 13.04M | 20.42M |
| TotalNonCurrentAssets | 2.11M | 2.14M | 2.06M | 2.10M |
| OtherNonCurrentAssets | 3.00K | 3.00K | 3.00K | 3.00K |
| NonCurrentPrepaidAssets | 189.00K | |||
| InvestmentsAndAdvances | 0.00 | 0.00 | ||
| InvestmentinFinancialAssets | 0.00 | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 2.04M | 2.04M | 2.04M | 2.04M |
| OtherIntangibleAssets | 2.04M | 2.04M | 2.04M | 2.04M |
| NetPPE | 64.00K | 99.00K | 21.00K | 60.00K |
| GrossPPE | 64.00K | 99.00K | 21.00K | 60.00K |
| OtherProperties | 64.00K | 99.00K | 21.00K | 60.00K |
| BuildingsAndImprovements | 21.00K | 60.00K | ||
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 695.00K | 2.56M | 10.98M | 18.32M |
| OtherCurrentAssets | 95.00K | 219.00K | 554.00K | 789.00K |
| PrepaidAssets | 252.00K | |||
| CashCashEquivalentsAndShortTermInvestments | 600.00K | 2.34M | 10.43M | 17.53M |
| OtherShortTermInvestments | 0.00 | 7.61M | 10.64M | 3.44M |
| CashAndCashEquivalents | 600.00K | 2.34M | 2.81M | 6.89M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -8.52M | -8.35M | -8.21M | -8.01M |
| RepaymentOfDebt | -24.00K | 0.00 | ||
| IssuanceOfDebt | 608.00K | 0.00 | ||
| IssuanceOfCapitalStock | 6.15M | 112.00K | 567.00K | 0.00 |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 600.00K | 2.34M | 2.81M | 6.89M |
| BeginningCashPosition | 2.34M | 2.81M | 6.89M | 12.16M |
| EffectOfExchangeRateChanges | -23.00K | -8.00K | 60.00K | -224.00K |
| ChangesInCash | -1.72M | -469.00K | -4.13M | -5.05M |
| FinancingCashFlow | 6.87M | 112.00K | 567.00K | 0.00 |
| CashFlowFromContinuingFinancingActivities | 6.87M | 112.00K | 567.00K | 0.00 |
| NetOtherFinancingCharges | -7.00K | |||
| ProceedsFromStockOptionExercised | 132.00K | 0.00 | 0.00 | 6.02M |
| NetCommonStockIssuance | 6.15M | 112.00K | 567.00K | 0.00 |
| CommonStockIssuance | 6.15M | 112.00K | 567.00K | 0.00 |
| NetIssuancePaymentsOfDebt | 584.00K | 0.00 | ||
| NetShortTermDebtIssuance | 584.00K | 0.00 | ||
| ShortTermDebtPayments | -24.00K | 0.00 | ||
| ShortTermDebtIssuance | 608.00K | 0.00 | ||
| InvestingCashFlow | -62.00K | 7.77M | 3.51M | 2.96M |
| CashFlowFromContinuingInvestingActivities | -62.00K | 7.77M | 3.51M | 2.96M |
| NetInvestmentPurchaseAndSale | -62.00K | 7.77M | 3.51M | 2.96M |
| SaleOfInvestment | 188.00K | 8.25M | 17.19M | 16.18M |
| PurchaseOfInvestment | -250.00K | -481.00K | -13.69M | -13.22M |
| OperatingCashFlow | -8.52M | -8.35M | -8.21M | -8.01M |
| CashFlowFromContinuingOperatingActivities | -8.52M | -8.35M | -8.21M | -8.01M |
| ChangeInWorkingCapital | 1.79M | 937.00K | 703.00K | -172.00K |
| ChangeInPayablesAndAccruedExpense | 1.66M | 480.00K | 273.00K | 23.00K |
| ChangeInAccruedExpense | 69.00K | 0.00 | ||
| ChangeInInterestPayable | 69.00K | 0.00 | ||
| ChangeInPayable | 1.59M | 480.00K | 273.00K | 23.00K |
| ChangeInAccountPayable | 1.59M | 480.00K | 273.00K | 23.00K |
| ChangeInPrepaidAssets | 129.00K | 457.00K | 430.00K | -195.00K |
| OtherNonCashItems | 208.00K | 3.00K | -4.00K | 5.00K |
| StockBasedCompensation | 1.14M | 818.00K | 1.02M | 2.46M |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | -282.00K | -641.00K | -207.00K |
| OperatingGainsLosses | 1.22M | |||
| GainLossOnInvestmentSecurities | 62.00K | |||
| NetIncomeFromContinuingOperations | -12.88M | -9.83M | -9.29M | -10.08M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ARTL
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|